MEN1309 is the second monoclonal antibody to be developed in the collaboration between Menarini and OBT (Oxford BioTherapeutics).
MEN 1309 is a human monoclonal antibody conjugated to a potent cytotoxic agent, maytansin derivative, against a membrane antigen, CD205, which is over-expressed in many tumors such non-Hodgkin lymphoma (NHL) and solid tumors such a subtype of breast cancer
Antibodies conjugate to a toxin belong to a new class of biopharmaceuticals for the treatment of tumors that act via an innovative mechanism called ADC (Antibody Drug Conjugate).
Through this mechanism, MEN1309 exerts a potent and selective cytotoxic activity on tumor cells.
The biotechnological process for the production of MEN1309 has been developed at Menarini Biotech in Pomezia.
MEN1309 has demonstrated an excellent anti-tumoral activity in different experimental xenograft models.
Non-clinical safety studies to support the first in human study have been completed. A phase I clinical trial in oncological patients is active in 4 European Countries (Belgium,Spain, United Kingdom, Italy) to identify the Maximum Tolerated Dose of the MEN1309.
VISIT OUR CLINICAL TRIALS DATABASE